Domainex welcomes interest from any potential collaborators, industrial or academic. If you would like to learn more about applying our drug-discovery platform to other targets, Please contact: ray.boffey@domainex.co.uk (www.domainex.co.uk) ➢ FLIP is a frequently overexpressed, key regulator of cell death and drug resistance in many cancers. ➢ A medicinal chemistry programme has identified first-in-class drug-like compounds capable of: ▪ Binding to FLIP with low and sub-micromolar activity AND disrupting FLIP's recruitment to the DISC in cancer cells ▪ Inducing apoptosis as a single agent AND promoting TRAIL-and TNF-induced apoptosis ▪ Retarding growth of NSCLC xenografts as a single agent and in combination with a multivalent TRAIL agonist ▪ Enhancing standard-of-care chemotherapy in KRAS mutant CRC and NSCLC ▪ Demonstrating anti-proliferative activity against key immunosuppressive T reg cells ▪ Ablating colony formation and suppressing tumour regrowth following Osimertinib treatment in EGFR mutant NSCLC
. Schematic overview of programme. The complex formed following ligation of the Fas and TRAIL-R1/R2 (DR4/DR5) death receptors by their ligands (FasL/CD95 and TRAIL) is called the death-inducing signalling complex (DISC), which consists of the receptors, the adaptor molecule FADD, procaspase-8 and its regulator FLIP 1 . Similar complexes are formed downstream of TNFR1 and in response to infection and DNA damage. Interaction with death receptors exposes the FADD death effector domain (DED), which recruits procaspase-8 by interacting with its tandem DEDs 2 . Procaspase-8 homo-dimerization results in conformational changes in its catalytic domains that lead to its activation and initiation of apoptosis 3 .
FLIP can also bind at the DISC and regulate procaspase-8 processing: its short splice form FLIP(S) blocks procaspase-8 processing and activation; however the long spice form FLIP(L) can activate or inhibit procaspase-8 processing depending on its expression levels 4 . FLIP is frequently over-expressed in NSCLC, colorectal, prostate and other cancers and correlates with adverse disease outcome 1 .
FLIP overexpression promotes drug resistance, and RNAi-mediated FLIP down-regulation leads to:
• The induction of caspase-8-dependent apoptosis in FLIP "addicted" cancer models [5] [6] [7] • Enhanced TRAIL-and IAP-antagonist-induced apoptosis [8] [9] • Enhanced chemotherapy-induced apoptosis 5,6
Figure 2. Models of the inter-molecular interactions between FADD/FLIP and FADD/procaspase 8.
FLIP preferentially binds to the DED of FADD via its DED2, whereas procaspase-8 preferentially binds to FADD via its DED1. The main residues which are important for the interactions are highlighted: FLIP uses its F114 residue on the α2 helix to bind into a groove between α1/α4 helices in the DED of FADD with a reciprocal interaction from FADD H9 into the α2/α5 hydrophobic patch of FLIP; procaspase-8 uses the Y8 residue on its α1 helix to bind into the hydrophobic patch between the α2/α5 helices in FADD, with a reciprocal interaction from FADD F25 into the α1/α4 groove in procaspase-8. At higher DISC stimulation, the more lowly expressed FLIP becomes depleted, and the more highly expressed procaspase-8 is recruited to the α1/α4 face of FADD as well as the α2/α5 surface; 6. Under these conditions, interactions between co-localized procaspase-8-FADD-procaspase-8 intermediate trimers results in procaspase-8 dimerization bringing the catalytic domains together, resulting in processing and full activation of the enzyme and initiation of the apoptotic process.
Model of DISC Assembly

Lead Compound Profiles
Figure 6. QDD-30 retards the growth of A549 NSCLC xenografts in Balb/c nude mice as a single agent and this is further potentiated in combination with IZ-TRAIL.
Balb/c nude mice were inoculated with 2x10 6 A549 cells in each flank. After 8 days, mice were treated PO with 150 mg/kg FLIPi BID or vehicle. IZ-TRAIL was administered by daily i.p. injections of 100g. Treatment was administered daily, and tumor volume recorded as indicated. IZ-TRAIL was purified as previously described 10 .
In Vivo efficacy and Tolerability
Figure 8. QDD-30 ablates colony formation of cells surviving Osimertinib treatment in vitro and suppresses in vivo tumor regrowth in PC9 EGFR mutant NSCLC cells.
(A) PC9 cells were treated with Osimertinib for 3 days followed by FLIPi for an additional 4 days. Colonies were left to form and were fixed with methanol and stained with 0.5% crystal violet solution. 
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FLIP has also been demonstrated to play a critical role in maintaining the viability of immunosuppresive, tumor-promoting immune cells, e.g. Tregs and MDSCs. 
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QDD-30 decreases FLIP expression and increases Caspase-3 cleavage in A549 xenografts
FLIP
Figure 9. QDD-30 downregulates FLIP protein expression and increases Cleaved Caspase-3 in tumor tissue (day 21).
Formalin-fixed paraffinembedded (FFPE) tumor tissue sections were stained for FLIP (Abcam ab8421) and
Cleaved Caspase-3 (Abcam ab13847) by standard IHC protocols. 
Figure 5. Impact of FLIP inhibitors on Caspase-8 and FADD CRISPR KO models. (A) A549 parental and CRISPR
CASP8 KO cells were treated with QDD-42 or QDD-30. Cell death was assessed 48h posttreatment by PI/Annexin V staining using high content microscopy. (B) A549 parental and CRISPR FADD KO cells were treated with QDD-42 or QDD-30. Cell death was assessed 48h posttreatment by PI/Annexin V staining using high content microscopy. 
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